Lexaria's strategy is to continue developing and optimizing our wholly-owned DehydraTECH™ drug delivery platform for application in the GLP-1 space, positioning it as a 'must-have' technology for ...

THURSDAY, Nov. 7, 2024 (HealthDay News) -- The head of the company that makes the diabetes and obesity drugs Ozempic and ...

The rush for weight loss drugs like Wegovy and diabetes drugs like Ozempic (which is also used for weight loss) has drained ...

Insulin prices have skyrocketed in recent years, working a hardship on the growing number of diabetics in the US. Progressive ...

Novo Nordisk has abandoned a drug it licensed from KBP Biosciences last year in a deal valued at up to $1.3 billion after it missed the mark in a chronic kidney disease (CKD) trial.

In October, it also asked the FDA to ban compounding pharmacies from making copycat versions of Wegovy and Ozempic, which it said were too complex for those manufacturers to produce safely. Meanwhile, ...

highlighting the need for more stringent oversight. Novo Nordisk has urged the FDA to prohibit the compounding of their drugs, citing complex manufacturing requirements.

"This is a forward-looking statement, mathematically based, and we'll come back with the more detailed guidance come early February 2025," Knudsen said. He said that absolute sales growth last year ...

Ozempic (semaglutide) may impact kidney health in certain people, especially those with diabetes. Learn more about what the ...

Novo Nordisk is one of the most mentioned companies in the U.S. across all news items in the past 12 hours, according to Factiva data. The maker of blockbuster weight-loss drugs Wegovy and Ozempic ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...